NVCR NovoCure Limited

NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...

NovoCure (NVCR) is back in focus after the company confirmed that long-serving director Timothy Scannell retired from its board on September 2, 2026, following five years of service. The modest 0.85% 1 day share price return and 3.22% 7 day share price return leave NovoCure trading at US$16.67. At the same time, a 27.06% year to date share price return and 28.23% 1 year total shareholder return contrast with a much weaker 5 year total shareholder return, suggesting recent momentum is building...

NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. Chief Executive Officer Frank Leonard said the company, founded more th

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

NovoCure (NVCR) drew fresh investor attention after raising its 2026 net revenue guidance to a range of US$710 million to US$725 million, following a quarter of record sales and active patient growth. See our latest analysis for NovoCure. The recent guidance upgrade and record quarter come after a sharp swing in sentiment around NovoCure, with the stock gaining 41.54% on a 3 month share price return and 46.59% on a 1 year total shareholder return. However, longer term total shareholder...

Moby summary of NovoCure Limited's Q2 2026 earnings call

Investors rewarded strong execution, improving profits and raised outlook.